Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20555-20569

  Sibbesen, Nina A ^a   Kopp, Katharina L ^a   Litvinov, Ivan V ^b   Jønson, Lars ^c   Willerslev Olsen, Andreas ^a   Fredholm, Simon ^a   Petersen, David L ^a   Nastasi, Claudia ^a   Krejsgaard, Thorbjørn ^a   Lindahl, Lise M ^d   Gniadecki, Robert ^e   Mongan, Nigel P ^f   Sasseville, Denis ^b   Wasik, Mariusz A ^g   Iversen, Lars ^d   Bonefeld, Charlotte M ^a   Geisler, Carsten ^a   Woetmann, Anders ^a   Odum, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c University of Copenhagen   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e Mental Health Center Glostrup   (Denmark)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cutaneous T cell lymphoma (CTCL); JAK3; miR 22; Mycosis fungoides (MF); STAT3; STAT5

Indexed keywords

BUTYRIC ACID; CURCUMIN; CYCLIN DEPENDENT KINASE 2; ENTINOSTAT; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE 3; MAX PROTEIN; MICRORNA 22; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MYCBP; PROTEIN NCOA1; REGULATOR PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; JAK3 PROTEIN, HUMAN; MICRORNA; MIRN22 MICRORNA, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STAT3 PROTEIN, HUMAN; TOFACITINIB;

ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; GENES, TUMOR SUPPRESSOR; HUMANS; JANUS KINASE 3; LYMPHOMA, T-CELL, CUTANEOUS; MICRORNAS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84940211242     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4111     Document Type: Article

References (81)

1. Zhang Q, Nowak I, Vonderheid EC, Rook A.H, Kadin ME, Nowell PC, Shaw LM, Wasik MA. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. U. S. A. 1996; 93:9148-53.
2. Nielsen M, Kaltoft K, Nordahl M, Röpke C, Geisler C, Mustelin T, Dobson P, Svejgaard A, Odum N. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. U. S. A. 1997; 94:6764-9.
3. Kopp KLM, Kauczok CS, Lauenborg B, Krejsgaard T, Eriksen KW, Zhang Q, Wasik MA, Geisler C, Ralfkiaer E, Becker JC, Ødum N, Woetmann A. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia 2010; 24:1179-85.
4. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Kneitz H, Eriksen KW, Lovato P, Zhang Q, Wasik MA, Geisler C, Ralfkiaer E, Becker JC, Ødum N. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood 2009; 113:5896-5904.
5. Zhang Y, Wang Y, Yu R, Huang Y, Su M, Xiao C, Martinka M, Dutz JP, Zhang X, Zheng Z, Zhou Y. Molecular Markers of Early-Stage Mycosis Fungoides. J. Invest. Dermatol. 2012; 132:1698-1706.
6. Huang Y, Su M-W, Jiang X, Zhou Y. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T cell lymphoma. Blood 2015; 125:1435-43.
7. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen A-M, Bovin LF, Gniadecki R, Geisler C, Ryder LP, Zhang Q, Wasik MA, Odum N et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia 2008; 22:2230-2239.
8. Chang T-P, Vancurova I. NF-κB function and regulation in cutaneous T-cell lymphoma. Am. J. Cancer Res. 2013; 3:433-45.
9. Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is over-expressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 2015. doi:http://dx.doi.org/10.1182/blood-2014-07-590398.
10. Dulmage BO, Geskin LJ. Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br. J. Dermatol. 2013; 169:1188-97.
11. Litvinov I V, Netchiporouk E, Cordeiro B, Zargham H, Pehr K, Gilbert M, Zhou Y, Moreau L, Woetmann A, Ødum N, Kupper TS, Sasseville D. Ectopic expression of embryonic stem cell and other developmental genes in Cutaneous T-Cell Lymphoma. Oncoimmunology 2014; 3:e970025, DOI:10.4161/21624011.2014.970025.
12. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, Nissen MH, Röpke C, Wasik MA, Odum N. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001; 15:787-93.
13. Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C, Eriksen KW, Woetmann A, Kaestel CG, Nissen MH, Ropke C, Skov S, Ødum N. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18:1288-95.
14. Kopp KL, Ralfkiaer U, Gjerdrum LMR, Helvad R, Pedersen IH, Litman T, Jønson L, Hagedorn PH, Krejsgaard T, Gniadecki R, Bonefeld CM, Skov L, Geisler C et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 2013; 12:1939-47.
15. Abraham RM, Zhang Q, Odum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol. Ther. 2011; 12:1019-1022.
16. Brender C, Lovato P, Sommer VH, Woetmann a, Mathiesen a-M, Geisler C, Wasik M, Ødum N. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005; 19:209-13.
17. Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, Billestrup N, Odum N. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97:1056-1062.
18. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am. J. Pathol. 2000; 157:1137-46.
19. Qin JZ, Dummer R, Burg G, Döbbeling U. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood 1999; 93:260-7.
20. Nielsen M, Nissen MH, Gerwien J, Zocca MB, Rasmussen HM, Nakajima K, Röpke C, Geisler C, Kaltoft K, Ødum N. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 2002; 99:973-977.
21. Marzec M, Halasa K, Kasprzycka M, Wysocka M, Liu X, Tobias JW, Baldwin D, Zhang Q, Odum N, Rook AH, Wasik MA. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res. 2008; 68:1083-91.
22. Krejsgaard T, Ralfkiaer U, Clasen-linde E, Eriksen KW, Kopp KL, Bonefeld CM, Geisler C, Dabelsteen S, Wasik MA, Ralfkiaer E, Woetmann A, Odum N. Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway. J. Invest. Dermatol. 2011:1331-1338.
23. Krejsgaard T, Litvinov I V, Wang Y, Xia L, Willerslev-olsen A, Koralov SB, Kopp KL, Bonefeld CM, Wasik MA, Geisler C, Woetmann A, Zhou Y, Sasseville D et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood: 2015; 122:943-951.
24. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth J a, Li L, Gooden F, Korenchuk S, Hou XS, Harrington E a, Randolph S, Reilly JF et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008; 68:3785-94.
25. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, Kopp KL, Vennegaard MT, Lauenborg B, Zibert JR, Krejsgaard T, Bonefeld CM, Søkilde R et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118:5891-900.
26. Marstrand T, Ahler CB, Ralfkiaer U, Clemmensen A, Kopp KL, Sibbesen N a, Krejsgaard T, Litman T, Wasik MA, Bonefeld CM, Grønbæk K, Gjerdum LMR, Gniadecki R et al. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. Leuk. Lymphoma 2013; 55:957-958.
27. Sandoval J, Díaz-Lagares A, Salgado R, Servitje O, Climent F, Ortiz-Romero PL, Pérez-Ferriols A, Garcia-Muret MP, Estrach T, Garcia M, Nonell L, Esteller M, Pujol RM et al. MicroRNA Expression Profiling and DNA Methylation Signature for Deregulated MicroRNA in Cutaneous T-Cell Lymphoma. J Invest Dermatol. 2015; 135:1128-37.
28. Ralfkiaer U, Lindal L, Litman T, Gjerdrum L-M, Busch Ahler C, Gniadecki R, Marstrand T, Fredholm S, Iveren L, Wasik M, Bonefeld CM, Geisler C, Krejsgaard T et al. MicroRNA Expression in Early Mycosis Fungoides Is Distinctly Different from Atopic Dermatitis and Advanced Cutaneous T-Cell Lymphoma. Anticancer Res 2014; 34:7207-7218.
29. Van der Fits L, van Kester MS, Qin Y, Out-Luiting JJ, Smit F, Zoutman WH, Willemze R, Tensen CP, Vermeer MH. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome. J. Invest. Dermatol. 2011; 131:762-8.
30. Van Kester MS, Ballabio E, Benner MF, Chen XH, Saunders NJ, van der Fits L, van Doorn R, Vermeer MH, Willemze R, Tensen CP, Lawrie CH. miRNA expression profiling of mycosis fungoides. Mol. Oncol. 2011; 5:273-80.
31. Moyal L, Barzilai A, Gorovitz B, Hirshberg A, Amariglio N, Jacob-Hirsch J, Maron L, Feinmesser M, Hodak E. miR-155 is involved in tumor progression of mycosis fungoides. Exp. Dermatol. 2013; 22(Lcm):431-433.
32. Di Leva G, Garofalo M, Croce CM. MicroRNAs in Cancer. Annu. Rev. Pathol. Mech. Dis. 2014; 9(1):287-314.
33. Baranwal S, Alahari SK. miRNA control of tumor cell invasion and metastasis. Int. J. Cancer 2011; 126:1283-1290.
34. Walsh C a, Qin L, Tien JC-Y, Young LS, Xu J. The function of steroid receptor coactivator-1 in normal tissues and cancer. Int. J. Biol. Sci. 2012; 8:470-85.
35. Li B, Song Y, Liu T-J, Cui Y-B, Jiang Y, Xie Z-S, Xie S-L. miRNA-22 suppresses colon cancer cell migration and invasion by inhibiting the expression of T-cell lymphoma invasion and metastasis 1 and matrix metalloproteinases 2 and 9. Oncol. Rep. 2013; 29:1932-8.
36. Alvarez-Díaz S, Valle N, Ferrer-Mayorga G, Lombardía L, Herrera M, Domínguez O, Segura MF, Bonilla F, Hernando E, Muñoz A. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum. Mol. Genet. 2012:1-9.
37. Ting Y, Medina DJ, Strair RK, Schaar DG. Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. Biochem. Biophys. Res. Commun. 2010; 394:606-11.
38. Xiong J. Emerging roles of microRNA-22 in human disease and normal physiology. Curr. Mol. Med. 2012; 12:247-58.
39. Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z, Zhou W. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br. J. Cancer 2010; 103:1215-1220.
40. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, Becker JC, Ødum N. Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006; 20:1759-66.
41. Niu G, Wright KL, Ma Y, Gabriela M, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Wright GM, Chen J et al. Role of Stat3 in Regulating p53 Expression and Function Role of Stat3 in Regulating p53 Expression and Function. Mol. Cell. Biol. 2005; 25:7432-7440.
42. Zhang Q, Wang HY, Liu X, Bhutani G, Kantekure K, Wasik M. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc. Natl. Acad. Sci. U. S. A. 2011; 108:11977-82.
43. Barnes NA, Stephenson S, Cocco M, Tooze RM, Doody GM. BLIMP-1 and STAT3 counterregulate microRNA-21 during plasma cell differentiation. J. Immunol. 2012; 189:253-60.
44. Mandal M, Powers SE, Maienschein-Cline M, Bartom ET, Hamel KM, Kee BL, Dinner AR, Clark MR. Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat. Immunol. 2011; 12:1212-20.
45. Mitchell T, Whittaker S, John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res. 2003; 63:9048-9054.
46. Heltemes-Harris LM, Willette MJL, Vang KB, Farrar MA. The role of STAT5 in the development, function, and transformation of B and T lymphocytes. Ann. N. Y. Acad. Sci. 2011; 1217:18-31.
47. Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 2007; 26:224-233.
48. Miklossy G, Hillard TS, Turkson J. Therapeutic modulators of STAT signalling for human disease. Nat. Rev. Drug Discov. 2013; 12:611-629.
49. Hour T-C, Chen J, Huang C-Y, Guan J-Y, Lu S-H, Pu Y-S. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate 2002; 51:211-218.
50. Ninomiya S, Tyybäkinoja A, Borze I, Räty R, Saarinen-Pihkala UM, Usvasalo A, Elonen E, Knuutila S. Integrated analysis of gene copy number, copy neutral LOH, and microRNA profiles in adult acute lymphoblastic leukemia. Cytogenet. Genome Res. 2012; 136:246-55.
51. Lionetti M, Musto P, Martino M Di. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin. cancer Res. 2013; 19:3130-42.
52. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Lambertenghi D. G, Neri A. Integrative High-resolution Microarray Analysis of Human Myeloma Cell Lines Reveals Deregulated miRNA Expression Associated with Allelic Imbalances and Gene Expression Profiles. Genes. Chromosomes Cancer 2009; 48:521-531.
53. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS, Piva R, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood 2013; 122:2083-92.
54. Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, Koike K. MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators. Biochem. Biophys. Res. Commun. 2011; 411:826-31.
55. Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene 2010; 22:4980-4988.
56. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi R-U, Takata T, Shimamoto A, Ochiya T, Tahara H. miR-22 represses cancer progression by inducing cellular senescence. J. Cell Biol. 2011; 193:409-24.
57. Huang S, Wang S, Bian C, Yang Z, Zhou H, Zeng Y, Li H, Han Q, Zhao RC. Upregulation of miR-22 Promotes Osteogenic Differentiation and Inhibits Adipogenic Differentiation of Human Adipose Tissue-Derived Mesenchymal Stem Cells by Repressing HDAC6 Protein Expression. Stem Cells Dev. 2012. doi:10.1089/scd.2012.0014.
58. Ballabio E, Mitchell T, van Kester MS, Taylor S, Dunlop HM, Chi J, Tosi I, Vermeer MH, Tramonti D, Saunders NJ, Boultwood J, Wainscoat JS, Pezzella F et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010; 116:1105-13.
59. De Mattos SF, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, Edwards CS, Martino A, Nelson BH, Francis JM, Jones MC, Brosens JJ, Coffer PJ, Lam EW-F. FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism. Mol. Cell. Biol. 2004; 24:10058-10071.
60. Ramadoss P, Unger-Smith NE, Lam FS, Hollenberg AN. STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol. Endocrinol. 2009; 23(June 2009):827-837.
61. Heltemes-Harris LM, Farrar MA. The Role of STAT5 in Lymphocte Decelopment and Transformation. Curr. Opin. Immunol. 2012; 24:146-152.
62. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. STAT3-and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. PNAS 2005; 102:1-6.
63. Tan G, Shi Y, Wu Z-H. MicroRNA-22 promotes cell survival upon UV radiation by repressing PTEN. Biochem. Biophys. Res. Commun. 2012; 417:546-51.
64. Bissonnette RP, McGahon A, Mahboubi A, Green DR. Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. J. Exp. Med. 1994; 180:2413-2418.
65. Van Doorn R. Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sezary Syndrome Identified by Gene Expression Analysis. Cancer Res. 2004; 64:5578-5586.
66. Walsh C a, Bolger JC, Byrne C, Cocchiglia S, Hao Y, Fagan A, Qin L, Cahalin A, McCartan D, McIlroy M, O'Gaora P, Xu J, Hill AD et al. Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis. Cancer Res. 2014. doi:10.1158/0008-5472.CAN-13-2133.
67. Wang S, Yuan Y, Liao L, Kuang S-Q, Tien JC-Y, O'Malley BW, Xu J. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc. Natl. Acad. Sci. U. S. A. 2009; 106:151-156.
68. McCartan D, Bolger JC, Fagan A, Byrne C, Hao Y, Qin L, McIlroy M, Xu J, Hill AD, ó Gaora P, Young LS. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res. 2012; 72:220-229.
69. McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S, O'Hara J, Tibbitts P, Hill ADK, Young LS. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res. 2012; 72:548-59.
70. Redmond AM, Bane FT, Stafford AT, Mcllroy M, Dillon MF, Crotty TB, Hill AD, S.Young L. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin. Cancer Res. 2009; 15:2098-2106.
71. Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O'Higgins NJ, Hill ADK, Young LS. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J. Clin. Pathol. 2004; 57:1069-1074.
72. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J. Steroid Biochem. Mol. Biol. 2000; 74:255-259.
73. Yu H, Wu M, Zhao P, Huang Y, Wang W, Yin W. Neuroprotective effects of viral overexpression of microRNA-22 in rat and cell models of cerebral ischemia-reperfusion injury. J Cell Biochem 2014; 241:233-241.
74. Berger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M et al. contribution to the clinical efficacy of extracorporeal photochemotherapy Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood 2011; 116:4838-4847.
75. Lanford RE, Hildebrandt-eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198-201.
76. Kaltoft K, Hansen BH, Pedersen CB, Pedersen S, Thestrup-Pedersen K. Common clonal chromosome aberrations in cytokine-dependent continuous human T-lymphocyte cell lines. Cancer Genet. Cytogenet. 1995; 85:68-71.
77. Woetmann A, Lovato P, Eriksen KW, Krejsgaard T, Labuda T, Zhang Q, Mathiesen A-M, Geisler C, Svejgaard A, Wasik MA, Odum N. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 2007; 109:3325-3332.
78. Eriksen KW, Woetmann A, Skov L, Krejsgaard T, Bovin LF, Hansen ML, Grønbaek K, Billestrup N, Nissen MH, Geisler C, Wasik M a, Ødum N. Deficient SOCS3 and SHP-1 expression in psoriatic T cells. J. Invest. Dermatol. 2010; 130:1590-1597.
79. Krejsgaard T, Willerslev-Olsen A, Lindahl LM, Bonefeld CM, Koralov SB, Geisler C, Wasik MA, Gniadecki R, Kilian M, Iversen L, Woetmann A, Odum N. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood 2014; 124:761-770.
80. Geisler C, Dietrich J, Nielsen BL, Kastrup J, Lauritsen JPH, Ødum N, Christensen MD. Leucine-based receptor sorting motifs are dependent on the spacing relative to the plasma membrane. J. Biol. Chem. 1998; 273:21316-21323.
81. Hofmann B, Odum N, Platz P, Ryder LP, Svejgaard A, Neilsen JO. Immunological studies in acquired immunodeficiency syndrome. Functional studies of lymphocyte subpopulations. Scand. J. Immunol. 1985; 21:235-243.